Tresiba is a new insulin developed by NovoNordisk. It is a very a long acting basal background insulin that is released into the blood stream in a very consistent way. Studies comparing Lantus Insulin to Tresiba have demonstrated that people using Tresiba (insulin degludec) have a 30-50% lower rate of hypoglcaemia (low blood sugar) compared to Lantus and this was most obvious through the night.
The dose of Tresiba insulin (insulin degludec) and Lantus insuli (insulin glargine)n is the same so changing from Lantus is simple. The very long action of Tresiba means that it takes 5 days for a new dose to settle (compared to 3 days with Lantus).
Tresiba can be combined with rapid acting Novorapid (Novolog) in a 70%/30% ratio. This insulin is called Ryzodeg insulin (to lean more go to the Ryzodeg page ).